Vinay K. Pulimamidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vinay K. Pulimamidi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Elsayed Elbasiony
Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA; and
1 shared publication - Reza Dana
Laboratory of Ocular Immunology, Transplantation and Regeneration, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
1 shared publication - Sharad K. Mittal
Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA; and
1 shared publication - Sunil K. Chauhan
Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA; and
1 shared publication - Susan Od Orr
Claris Biotherapeutics, Inc., Jersey City, NJ
1 shared publication - Tomi Od Luan
Claris Biotherapeutics, Inc., Jersey City, NJ
1 shared publication
Latest Publications
- Open Access
- 10 July 2025
- Published by Wolters Kluwer Health in Cornea
- Vol. 44 (10) , 1296-1302
Topical Hepatocyte Growth Factor Accelerates Wound Healing and Inhibits Scarring in Experimental Corneal Injury
Purpose: The aim of this study was to compare the rates of healing, scar formation, and regression of preexisting scars using topical murine hepatocyte growth factor (mHGF), recombinant human deleted HGF (dHGF), murine nerve growth factor (mNGF), and phosphate-buffered saline (PBS). Methods: Mechanical corneal epithelial and stromal injury was induced in C57BL/6 mice. Five groups of mice were studied in each of phase I (wound healing and scar formation) and phase II (regression of preexisting scars). Each group received topical 0.1% mHGF, 0.1% dHGF, 0.2% dHGF, 0.1% mNGF, or PBS. In phase I, animals were dosed 4 times/day (QID) on days 0 to 7. In phase II, a corneal injury was induced, and no treatment was administered for 10 days to allow scar formation. Mice with scars were then dosed QID on days 11 to 21. Ocular assessments included slit-lamp photography (phase I and II) and fluorescein staining (phase I). Results: In phase I, eyes treated with mHGF exhibited significantly faster epithelial healing and decreased scar formation compared with both mNGF-treated and PBS-treated eyes 7 days after treatment. Consistent with that seen in mHGF-treated eyes, 0.1% and 0.2% dHGF-treated eyes each showed significantly faster epithelial healing compared with PBS-treated eyes. Scars formed in dHGF-treated eyes were also significantly smaller than PBS-treated eyes 7 days after treatment. In phase II, both mHGF-treated and dHGF-treated eyes showed a significant decrease in the size of preexisting scars compared with PBS-treated eyes. Conclusions: Topical HGF significantly accelerates corneal wound healing, reduces scar formation, and can reverse preexisting scars.
- 10 July 2025
- Published by Wolters Kluwer Health in Cornea
- Vol. 44 (10) , 1296-1302
Open AccessTopical Hepatocyte Growth Factor Accelerates Wound Healing and Inhibits Scarring in Experimental Corneal Injury
Purpose: The aim of this study was to compare the rates of healing, scar formation, and regression of preexisting scars using topical murine hepatocyte growth factor (mHGF), recombinant human deleted HGF (dHGF), murine nerve growth factor (mNGF), and phosphate-buffered saline (PBS). Methods: Mechanical corneal epithelial and stromal injury was induced in C57BL/6 mice. Five groups of mice were studied in each of phase I (wound healing and scar formation) and phase II (regression of preexisting scars). Each group received topical 0.1% mHGF, 0.1% dHGF, 0.2% dHGF, 0.1% mNGF, or PBS. In phase I, animals were dosed 4 times/day (QID) on days 0 to 7. In phase II, a corneal injury was induced, and no treatment was administered for 10 days to allow scar formation. Mice with scars were then dosed QID on days 11 to 21. Ocular assessments included slit-lamp photography (phase I and II) and fluorescein staining (phase I). Results: In phase I, eyes treated with mHGF exhibited significantly faster epithelial healing and decreased scar formation compared with both mNGF-treated and PBS-treated eyes 7 days after treatment. Consistent with that seen in mHGF-treated eyes, 0.1% and 0.2% dHGF-treated eyes each showed significantly faster epithelial healing compared with PBS-treated eyes. Scars formed in dHGF-treated eyes were also significantly smaller than PBS-treated eyes 7 days after treatment. In phase II, both mHGF-treated and dHGF-treated eyes showed a significant decrease in the size of preexisting scars compared with PBS-treated eyes. Conclusions: Topical HGF significantly accelerates corneal wound healing, reduces scar formation, and can reverse preexisting scars.